Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial

Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial

Background. Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate to severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 trial. Aim. To evaluate the efficacy and safety of two...

Full description

Saved in:
Bibliographic Details
Main Authors: Luis Puig, Andrey L. Bakulev, Muza M. Kokhan, Alexey V. Samtsov, Vladislav R. Khairutdinov, Maria A. Morozova, Nikita A. Zolkin, Ivan V. Kuryshev, Alexey N. Petrov, Antonina V. Artemeva, Arina V. Zinkina-Orikhan
Format: article
Language:RU
Published: State Scientific Center of Dermatovenereology and Cosmetology 2021
Subjects:
psoriasis
monoclonal antibodies
interleukin-17 inhibitors
Dermatology
RL1-803
Online Access:https://doaj.org/article/e87e2e9dcfab4ce2ac14f940344d122b
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/e87e2e9dcfab4ce2ac14f940344d122b

Similar Items